Judith Gilmore, MD
Endocrinology, Diabetes & Metabolism · Wakefield, RINPI 1114003209
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,352 and has fallen 74.0% since, to $612 in 2025.
Across 265 payments — averaging $42.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$2K
- Boehringer Ingelheim$2K
- Abbott$1K
- Lilly USA, LLC$778
- Corcept Therapeutics$741
- AstraZeneca$646
- plus $4K from 22 others
What the payments were for
- Food & beverage$11,094100%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 42 | $2,164 |
| Boehringer Ingelheim | 39 | $1,986 |
| Abbott | 18 | $1,093 |
| Lilly USA, LLC | 20 | $778 |
| Corcept Therapeutics | 20 | $741 |
| AstraZeneca(2 entities) | 12 | $646 |
| AbbVie | 26 | $557 |
| Bayer | 12 | $486 |
| Amarin Pharma, Inc. | 22 | $396 |
| Amgen | 5 | $387 |
| Xeris Pharmaceuticals, Inc. | 8 | $364 |
| Johnson & Johnson | 7 | $317 |
| Novo Nordisk | 3 | $307 |
| Ultragenyx Pharmaceutical Inc. | 4 | $155 |
| Novartis | 2 | $127 |
| Radius Health, Inc. | 1 | $123 |
| Amneal Pharmaceuticals LLC | 6 | $122 |
| Mannkind Corporation | 5 | $98 |
| Valeritas, Inc. | 3 | $73 |
| Scilex Pharmaceuticals Inc. | 1 | $44 |
| Merck | 2 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $23 |
| IBSA Pharma Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Emergent Biosolutions Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,130 in reported general payments places this provider in the 75th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
See all endocrinology, diabetes & metabolism providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 11 | $277,866 |
| OzempicSemaglutide | 129 | $155,984 |
| JardianceEmpagliflozin | 99 | $88,049 |
| TrulicityDulaglutide | 50 | $54,768 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $41,367 |
| MounjaroTirzepatide | 21 | $28,578 |
| JanuviaSitagliptin Phosphate | 21 | $23,195 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $20,850 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $20,213 |
| KerendiaFinerenone | 20 | $15,157 |
| RybelsusSemaglutide | 12 | $10,756 |
| SynthroidLevothyroxine Sodium | 83 | $9,835 |
| Humalog Mix 50-50 KwikpenInsulin Lispro Protamin/Lispro | 17 | $5,244 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 52 | $3,673 |
| Levothyroxine Sodium | 107 | $1,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $741 | $277,86611 claims |
| Novo NordiskOzempic, Rybelsus | $307 | $166,740141 claims |
| Boehringer IngelheimJardiance | $1,986 | $88,04999 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $778 | $83,34671 claims |
| MerckJanuvia | $25 | $23,19521 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $2,164 | $20,85025 claims |
| BayerKerendia | $486 | $15,15720 claims |
| AbbVieSynthroid | $557 | $9,83583 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $122 | $2,643169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
Other endocrinology, diabetes & metabolism in Wakefield
- Robert DobrzynskiProvidence$245K
- Frank D'alessandroNorth Providence$193K
- Ricardo Correa MarquezEast Providence$94K
- Robert SmithProvidence$80K
- Sudhir BansalWarwick$38K
- Joseph TucciProvidence$30K
- Stephanie CurryJohnston$8K
- Beatriz DemoranvilleWarwick$5K
- Raquel CarneiroRiverside$3K
- Manchin ChangProvidence$878
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.